Type 2 diabetic

By Targets:	Aldose Reductase (1) Apoptosis (1) Endogenous Metabolite (1) Free Fatty Acid Receptor (2) GCGR (1) Glucosidase (2) HBV (1) Insulin Receptor (1) Isotope-Labeled Compounds (1) Leukotriene Receptor (1) Neuropeptide Y Receptor (2) Potassium Channel (2) PPAR (3)
By Research Areas:	Cardiovascular Disease (2) Infection (1) Inflammation/Immunology (1) Metabolic Disease (15) Neurological Disease (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B1114

Gliquidone

AR-DF 26
Others Metabolic Disease

Gliquidone (AR-DF 26) is an anti-diabetic agent in the sulfonylurea class, used in the treatment of diabetes mellitus type 2.

Gliquidone AR-DF 26	Others	Metabolic Disease
Gliquidone (AR-DF 26) is an anti-diabetic agent in the sulfonylurea class, used in the treatment of diabetes mellitus type 2.

HY-N1995

Methylswertianin
Methylswertianin is an active constituent in Swertia punicea Hemsl, with anti-diabetic effect. Methylswertianin can abates type-2 diabetes, likely via the improvement of insulin resistance (IR) .

HY-105074

Farglitazar

GI262570; GI262570X
PPAR Metabolic Disease

Farglitazar is a PPARγ agonist that has significant therapeutic benefits such as glycemic control in type 2 diabetic patients.

Farglitazar GI262570; GI262570X	PPAR	Metabolic Disease
Farglitazar is a PPARγ agonist that has significant therapeutic benefits such as glycemic control in type 2 diabetic patients.

HY-120956

Methyl stearidonate	Others	Metabolic Disease
Methyl stearidonate is a secondary metabolite that can be isolated from Padina tenuis. Methyl stearidonate can be used for the research of type 2 diabetic .

HY-144231

SIK1 activator 1	Others	Metabolic Disease
SIK1 activator 1 exhibited remarkable inhibitory activity on hepatic gluconeogenesis by enhancing the SIK1 phosphorylation and ameliorated the hyperglyceamia of type 2 diabetic mice.

HY-B1114S

Gliquidone-d6 AR-DF 26-d₆	Isotope-Labeled Compounds	Metabolic Disease
Gliquidone-d₆ is deuterium labeled Gliquidone. Gliquidone (AR-DF 26) is an anti-diabetic agent in the sulfonylurea class, used in the treatment of diabetes mellitus type 2.

HY-16421

Ragaglitazar (-)-DRF 2725; NNC 61-0029	PPAR	Metabolic Disease
Ragaglitazar is a PPARα and PPARγ agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic.

HY-13633

Exisulind 1 Publications Verification	Aldose Reductase	Metabolic Disease
Exisulind is an inactive metabolite of the nonsteroidal, anti-inflammatory agent sulindac . Exisulind inhibits aldose reductase with an IC₅₀ of 367 nM in vitro and may contribute to the beneficial pharmacological effects of sulindac on type 2 diabetic complications .

HY-B0254

Glipizide CP 28720; K 4024	Potassium Channel	Metabolic Disease
Glipizide (CP 2872; K 4024) a potent, orally active and sulfonylurea class *anti-diabetic* agent and can be used for type 2 diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium (K_ATP) channels among β cells of pancreatic islets of Langerhans .

HY-122124

CAY10583	Leukotriene Receptor	Inflammation/Immunology
CAY10583 is a potent and selective full Leukotriene B4 receptor type 2 (BLT2) agonist. CAY10583 directly promotes keratinocyte migration in vitro and accelerates wound closure in vivo. CAY10583 is a promising pharmaceutical agent for diabetic wounds .

HY-W010655

Fasiglifam hemihydrate TAK-875 hemihydrate	Free Fatty Acid Receptor	Metabolic Disease
Fasiglifam (TAK-875) hemihydrate is a potent, selective and orally active GPR40 agonist with EC₅₀ of 72 nM. Fasiglifam enhances glucose-dependent insulin secretion and improves hyperglycemia in type 2 diabetic rats. Fasiglifam can induce liver injury .

HY-B0254S

Glipizide-d11	Potassium Channel	Metabolic Disease
Glipizide-d₁₁ is the deuterium labeled Glipizide. Glipizide (CP 2872; K 4024) a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2 diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium (KATP) channels among β cells of pancreatic islets of Langerhans[1][2].

HY-101292

FK614	PPAR	Metabolic Disease
FK614 is an orally active, non-thiazolidinedione (TZD) type, and selective PPARγ modulator (SPPARM). FK614 functions as a PPARγ agonist with potent anti-diabetic activity in vivo. FK614 has different effects on the activation of PPARγ at each stage of adipocyte differentiation. FK614 can be used for the research of hyperglycemia, hypertriglyceridemia, glucose intolerance and type 2 diabetes .

HY-152158

α-Glucosidase-IN-22	Glucosidase	Metabolic Disease
α-Glucosidase-IN-22 (compound 7i), a benzimidazole, is a potent α-glucosidase inhibitor with an IC₅₀ of 0.64 μM. α-Glucosidase-IN-22 is a potent anti-diabetic agent and has the potential for type 2 diabetes mellitus (T2DM) research .

HY-P1131

M617	Neuropeptide Y Receptor	Cardiovascular Disease
M617 is a selective galanin receptor 1 (GAL1) agonist, with K_is of 0.23 and 5.71 nM for GAL1 and GAL2, respectively. M617, acting through its central GAL1, can promote GLUT4 expression and enhance GLUT4 content in the cardiac muscle of type 2 diabetic rats .

HY-P1131A

M617 TFA	Neuropeptide Y Receptor	Cardiovascular Disease
M617 TFA is a selective galanin receptor 1 (GAL1) agonist, with K_is of 0.23 and 5.71 nM for GAL1 and GAL2, respectively. M617 TFA, acting through its central GAL1, can promote GLUT4 expression and enhance GLUT4 content in the cardiac muscle of type 2 diabetic rats .

HY-P3542

Des His1, Glu8 Exendin-4	GCGR	Metabolic Disease
Des His1, Glu8 Exendin-4 is a potent glucagon-like peptide-1 receptor (GLP-1-R) antagonist. Des His1, Glu8 Exendin-4 improves glucose homeostasis by regulating both insulin secretion and glucose production. Des His1, Glu8 Exendin-4 can be used for the research of type 2 diabetic and gastrointestinal .

HY-N0058

4,5-Dicaffeoylquinic acid 4 Publications Verification Isochlorogenic acid C	HBV Endogenous Metabolite Apoptosis Glucosidase	Infection
4,5-Dicaffeoylquinic acid (Isochlorogenic acid C) is an antioxidant, can be isolated from Gynura divaricata and Laggera alata. 4,5-Dicaffeoylquinic acid reduces islet cell apoptosis and improves pancreatic function in type 2 diabetic mice, and has obvious inhibitory activities against yeast α-glucosidase. 4,5-Dicaffeoylquinic acid inhibits prostate cancer cells through cell cycle arrest. 4,5-Dicaffeoylquinic acid also has anti-apoptotic, anti-injury and anti-hepatitis B virus effects .

HY-147678

GPR40 agonist 5	Free Fatty Acid Receptor	Metabolic Disease
GPR40 agonist 5 (compound I-14) is an orally active and potent GPR40 (G protein coupled receptor 40) agonist, with an EC₅₀ of 47 nM. GPR40 agonist 5 decreases the levels of blood glucose and improves the glucose tolerance. GPR40 agonist 5 has sufficient effectiveness for the control of hyperglycemia state in type 2 diabetic mice . GPR40 agonist 5 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-P3247

[D-Ala2]-GIP (human)	Insulin Receptor	Neurological Disease Metabolic Disease
[D-Ala2]-GIP (human) is a GIP receptor agonist. [D-Ala2]-GIP (human) improves glucose tolerance. [D-Ala2]-GIP (human) shows neuroprotective activity in MPTP-induced Parkinson's disease model. [D-Ala2]-GIP (human) also improves cognitive function and hippocampal synaptic plasticity in obese diabetic rats. [D-Ala2]-GIP (human) can be used for research of type 2 diabetes, Parkinson's disease, etc

Cat. No.	Product Name

HY-L040

Anti-diabetic Compound Library	740 compounds
Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage. The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes. MCE Anti-diabetic Compound Library owns a unique collection of 740 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Anti-diabetic Compound Library

740 compounds

Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage.

The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes.

MCE Anti-diabetic Compound Library owns a unique collection of 740 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Cat. No.	Product Name	Target	Research Area

HY-P1131A

M617 TFA	Neuropeptide Y Receptor	Cardiovascular Disease
M617 TFA is a selective galanin receptor 1 (GAL1) agonist, with K_is of 0.23 and 5.71 nM for GAL1 and GAL2, respectively. M617 TFA, acting through its central GAL1, can promote GLUT4 expression and enhance GLUT4 content in the cardiac muscle of type 2 diabetic rats .

HY-P3247

[D-Ala2]-GIP (human)	Insulin Receptor	Neurological Disease Metabolic Disease
[D-Ala2]-GIP (human) is a GIP receptor agonist. [D-Ala2]-GIP (human) improves glucose tolerance. [D-Ala2]-GIP (human) shows neuroprotective activity in MPTP-induced Parkinson's disease model. [D-Ala2]-GIP (human) also improves cognitive function and hippocampal synaptic plasticity in obese diabetic rats. [D-Ala2]-GIP (human) can be used for research of type 2 diabetes, Parkinson's disease, etc

HY-P3542

Des His1, Glu8 Exendin-4	GCGR	Metabolic Disease
Des His1, Glu8 Exendin-4 is a potent glucagon-like peptide-1 receptor (GLP-1-R) antagonist. Des His1, Glu8 Exendin-4 improves glucose homeostasis by regulating both insulin secretion and glucose production. Des His1, Glu8 Exendin-4 can be used for the research of type 2 diabetic and gastrointestinal .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0058

4,5-Dicaffeoylquinic acid 4 Publications Verification Isochlorogenic acid C	Infection Classification of Application Fields Ketones, Aldehydes, Acids Source classification Phenols Polyphenols Plants Bowdichia virgilioides Compositae Endogenous metabolite Disease Research Fields	HBV Endogenous Metabolite Apoptosis Glucosidase
4,5-Dicaffeoylquinic acid (Isochlorogenic acid C) is an antioxidant, can be isolated from Gynura divaricata and Laggera alata. 4,5-Dicaffeoylquinic acid reduces islet cell apoptosis and improves pancreatic function in type 2 diabetic mice, and has obvious inhibitory activities against yeast α-glucosidase. 4,5-Dicaffeoylquinic acid inhibits prostate cancer cells through cell cycle arrest. 4,5-Dicaffeoylquinic acid also has anti-apoptotic, anti-injury and anti-hepatitis B virus effects .

HY-120956

Methyl stearidonate	Structural Classification Natural Products Marine algae Source classification Marine natural products	Others
Methyl stearidonate is a secondary metabolite that can be isolated from Padina tenuis. Methyl stearidonate can be used for the research of type 2 diabetic .

Cat. No.	Product Name	Chemical Structure

HY-B0254S

Glipizide-d11
Glipizide-d₁₁ is the deuterium labeled Glipizide. Glipizide (CP 2872; K 4024) a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2 diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium (KATP) channels among β cells of pancreatic islets of Langerhans[1][2].

HY-B1114S

Gliquidone-d6

Gliquidone-d₆ is deuterium labeled Gliquidone. Gliquidone (AR-DF 26) is an anti-diabetic agent in the sulfonylurea class, used in the treatment of diabetes mellitus type 2.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds